| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
A positive Lyme disease antibody result may signal a need to consider other tick-borne pathogens, according to a study of 193,260 individuals tested at Quest Diagnostics. In the U.S. Northeast, 31.1% of people positive for B. burgdorferi also tested positive for at least one of those other three pathogens, Yonghong Li, PhD, of Quest Diagnostics in San Juan Capistrano, California, and colleagues reported in a JAMA Network Open research letter.
With CMS poised to release clinical lab payment rates with statutorily mandated reductions of up to 15%, Quest Diagnostics is highlighting a survey finding that consumers across party lines view lab tests as critical to their care and is urging Congress to pass the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act before the cuts kick in on Jan. 1.
With the US Food and Drug Administration (FDA) recently clearing two blood-based Alzheimer’s tests and additional regulatory clearances expected in the near future, the market for such assays is an increasingly crowded one. he clinical laboratory firms Quest Diagnostics and Laboratory Corporation of America offer both the FDA-cleared Roche and Fujirebio tests and their own laboratory-developed Alzheimer’s blood tests. “There is a little bit of difference in the performance of the tests,” said Michael Racke, medical director for neurology at Quest. He noted, for instance, that studies have indicated mass spectrometry (used by C2N in PrecivityAD2) may offer better measurement of plasma Aβ 40/42 than immunoassays, a finding that he said influenced Quest’s decision to use mass spec for its AD-Detect Alzheimer’s LDT. Different immunoassays have also shown differences in performance, he said.
Labcorp and Quest Diagnostics see solid growth on the horizon for laboratory companies as health systems try to blunt financial headwinds and patients seek more on-demand services. After acquiring lab assets from systems such as Minneapolis-based Allina Health, Columbus, Ohio-based OhioHealth, Franklin, Tennessee-based Community Health Systems and Fort Wayne, Indiana-based Parkview Health, the two dominant national commercial laboratory companies have set their focus on broadening test menus and direct-to-patient offerings.
Quest Diagnostics announced that Apple Health app users across most of the United States will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. The Quest laboratory panel is designed to deliver preventive health insights and includes biomarkers for assessing cardiometabolic health and organ function.